Based on the compelling data presented here it is apparent that a scrupulous determination of PDGFr-β and PDGF-B status in cancer cells must be undertaken before any therapies targeting the stromal component of pancreatic cancer are contemplated. Here, PDGFRB is linked to familial pancreatic carcinoma.